Emcure Pharma shares slip 3% today as Bain Capital likely offloads up to 2% stake in block deals for Rs 493 crore

Emcure Pharma

Shares of Emcure Pharmaceuticals fell 3 percent on Tuesday after a large block trade hit the exchanges, with roughly 40.6 lakh shares -- about 2.4 percent of the company’s equity -- changing hands in two block deals.

The transaction is likely linked to Bain Capital’s BC Investments, which had been expected to offload up to 2 percent of its stake, according to earlier news reports. Emcure Pharma stock was trading at Rs 1,352 around 11 am, extending its weak trend for 2025, down about 7.5 percent year to date.

According to a CNBC TV18 news report of Monday, BC Investments (Bain Capital) had planned to sell up to 2 percent of Emcure Pharma’s total equity through a block deal at an indicative floor price of Rs 1,296.51 per share. This implied a discount of roughly 7 percent to Monday’s closing price of Rs 1,394.10 on the NSE. The total deal size was estimated at up to Rs 493 crore, with a 90-day lock-in applying to the shares sold. BC Asia held a 6.3 percent stake in the company at the end of Q2 2025.

• Also read | Groww shares jump 6% today, extend post listing rally to 65% in 5 straight sessions

Details on the final buyers and the confirmed seller are expected once exchange disclosures are published.

Emcure Pharmaceuticals reported a strong July-September quarter, with consolidated net profit rising 25.1 percent year on year to Rs 243 crore, compared with Rs 194 crore a year earlier. Revenue from operations grew 13.4 percent to Rs 2,269.8 crore, supported by broad-based momentum across key therapeutic segments and sustained traction in both domestic and international markets.

EBITDA increased 25 percent to Rs 475.4 crore, while margins improved to 21 percent from 19 percent, aided by a better product mix and cost efficiencies. The company said growth was driven by continued strength in its India formulations business, along with healthy export demand across gynaecology, cardiovascular, HIV antivirals and pain management, as well as expansion in emerging markets through new launches and regulatory filings.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.